$STVN

FEDERICI WILLIAM J sold $26K of STVN

FEDERICI WILLIAM J sold 1,493 shares of Stevanato Group S.p.A. (STVN) at $17.09 on 2026-06-15.

Original reporting
SEC EDGAR · FEDERICI WILLIAM J
Published Jun 26, 2026, 10:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STVN
Neutral
medium confidence
Mentioned
$STVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The newest concrete fact is the director’s open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may monitor for patterns in insider activity, but this single sale lacks fundamental information to drive repricing.

03

What to watch

No 10b5-1 plan is stated, but the article provides no context on prior sales, compensation, or whether other insiders are selling concurrently.

Relevance 3/10Novelty 5/10Timing: new Form 4 filed 2026-06-26 (sale dated 2026-06-15)

Background

This is an SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A. (STVN).

Company-level read

Ticker impact

$STVNNeutralMedium confidence
Context

Stevanato Group director FEDERICI WILLIAM J filed a Form 4 open-market sale of 1,493 shares at $17.0900 on 2026-06-15.

Expected impact

Likely limited near-term impact; treat as low-signal unless follow-on selling accelerates.

Evidence & confidence

The filing is primary-source and company-specific, but it is a relatively small, single insider sale with no accompanying fundamental catalyst or guidance change.

Market effects

Minimal; this is an isolated insider transaction with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification/tax liquidity rather than a bearish view, especially with remaining holdings after the transaction.

Key entities

  • Stevanato Group S.p.A.

    Subject of the Form 4 insider transaction disclosure (STVN).

  • FEDERICI WILLIAM J

    Director who sold 1,493 shares in an open-market sale on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q2 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.